WebBased on its high activity as an anti-myeloma drug with a good tolerability profile, LEN is currently gaining interest in both preclinical and clinical research for combinatory treatments with novel agents including monoclonal antibodies, immunotoxins, tyrosine kinase inhibitors, new proteasome inhibitors and epigenetic-interfering agents as ... WebMar 30, 2024 · Keywords: multiple myeloma; novel agents; relapse. Conflict of interest statement . Financial & competing interests disclosureThis work is supported in part by the CTSA Grant UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH. This work is also supported in part by the Marion …
Bispecifics, trispecifics, and other novel immune treatments in myeloma …
WebDec 4, 2024 · Despite many recent drug approvals, relapses in multiple myeloma (MM) are inevitable. Patients who are pentarefractory (refractory to 2 IMiDs, 2 PIs, and an anti-CD38 monoclonal antibody) have particularly poor outcomes, with median overall survival (OS) of 5.6 months in 1 study. 1 Several novel immunotherapeutic approaches are under … WebAug 11, 2024 · Busulfan in combination with melphalan (BuMel) is a promising conditioning regimen for treatment of patients with newly-diagnosed multiple myeloma undergoing ASCT. In a 2024 clinical study a total of 205 patients were treated with either BuMel or high dose melphalan alone and directly compared. how to set up a youtube business
[Novel agents in multiple myeloma treatment].
WebOct 3, 2016 · The incorporation of novel agents such as bortezomib and lenalidomide into initial therapy for ... WebJan 7, 2009 · A therapeutic renaissance in the history of cancer therapy has been unfolding with the recent development of what has been termed the ‘novel agents’ for the treatment of multiple myeloma (MM). Less than a decade ago, MM therapy was in the doldrums and had been that way for decades. WebJan 9, 2024 · 1. Introduction. Multiple myeloma (MM), which accounts for 10–15% of all hematologic malignancies, arises from a terminally differentiated postgerminal center plasma cells in the bone marrow (BM) and is characterized by a monoclonal proliferation of plasma cells resulting in the production of monoclonal antibodies and end-organ damage … noth beach mast boad protectors